IL-33 (oxidation resistant) (human) (rec.) (untagged)

Catalog number: AG-40B-0160-C010
Brand: AdipoGen Life Sciences
Packing: 10 ug
Other sizes: Other sizes available
Price: € 240.00
Expected delivery time: 7 days
Quantity:

Product specifications for - IL-33 (oxidation resistant) (human) (rec.) (untagged)

Overview: 
Product group: Proteins / Signaling Molecule
Category: Chemokines / cytokines
Species: Human
Target: IL33
Target description: interleukin 33
Properties: 
Purity: >95% (SDS-PAGE)
Molecular weight: ~17kDa
Datasheet: Datasheet
  Research Use Only
UNSPSC: 12352202
Form supplied: Lyophilized. Contains PBS.
Storage instructions: 2-¦C to 8-¦C, -20-¦C
Scientific information: 
Scientific info: Interleukin-33 (IL-33; HF-NEV; IL-1F11), a member of the IL-1 family of cytokines, is expressed by many cell types following pro-inflammatory stimulation and is thought to be released upon cell lysis. IL-33 binds to and signals through ST2 (IL-1R1) and its stimulation recruits MYD88, IRAK, IRAK4 and TRAF6, followed by phosphorylation of ERK1 (MAPK3) / ERK2 (MAPK1), p38 (MAPK14) and JNK. The ability of IL-33 to target numerous immune cell types, like Th2-like cells, mast cells and B1 cells, and to induce cytokine and chemokine production underlines its potential in influencing the outcome of a wide range of diseases, such as arthritis, asthma, atopic allergy & anaphylaxis, cardiovascular disease/atherosclerosis, nervous system diseases and sepsis. IL-33 facilitates Treg expansion in vitro and in vivo. Recently, IL-33 has been involved in adipocyte differentiation. The biological activity of IL-33 at its receptor ST2 is rapidly terminated in the extracellular environment by its oxidation (formation of two disulfide bridges), resulting in an extensive conformational change that disrupts the ST2 binding site. Mutations at amino acids C208S/C232S protect IL-33 from oxidation and increase its activity. - Protein. Human IL-33 (aa 112-270) is untagged. Amino acids C208 and C232 have been mutated to serine to protect IL-33 from oxidation. Source: E. coli. Endotoxin content: <0.01EU/microg purified protein (LAL test; Lonza). Lyophilized. Contains PBS. Binds to human ST2. Purity: >95% (SDS-PAGE). Interleukin-33 (IL-33; HF-NEV; IL-1F11), a member of the IL-1 family of cytokines, is expressed by many cell types following pro-inflammatory stimulation and is thought to be released upon cell lysis. IL-33 binds to and signals through ST2 (IL-1R1) and its stimulation recruits MYD88, IRAK, IRAK4 and TRAF6, followed by phosphorylation of ERK1 (MAPK3) / ERK2 (MAPK1), p38 (MAPK14) and JNK. The ability of IL-33 to target numerous immune cell types, like Th2-like cells, mast cells and B1 cells, and to induce cytokine and chemokine production underlines its potential in influencing the outcome of a wide range of diseases, such as arthritis, asthma, atopic allergy & anaphylaxis, cardiovascular disease/atherosclerosis, nervous system diseases and sepsis. IL-33 facilitates Treg expansion in vitro and in vivo. Recently, IL-33 has been involved in adipocyte differentiation. The biological activity of IL-33 at its receptor ST2 is rapidly terminated in the extracellular environment by its oxidation (formation of two disulfide bridges), resulting in an extensive conformational change that disrupts the ST2 binding site. Mutations at amino acids C208S/C232S protect IL-33 from oxidation and increase its activity.
Gene ID: 90865
Swiss prot ID: Q2YEJ5
Safety information: 
MSDS: MSDS
Hazard information: Non-hazardous
Additional information: 
Synonyms: AG-40B-0160-C010; AdipoGen Life Sciences; C9orf26; DVS27; DVS27-related protein; IL1F11; interleukin-1 family member 11; interleukin-33; NFEHEV; NF-HEV; nuclear factor for high endothelial venules; nuclear factor from high endothelial venules
Oxidation of the alarmin IL-33 regulates ST2-dependent inflammation: E.S. Cohen, et al.; Nat. Commun. 6, ID8327 (2015) Read more